Skip to main content
OpenTrials

Clinical trial condition

Mantle Cell Lymphoma

Explore clinical trials studying Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.

252 public trials 60 recruiting studies
Refine in advanced search Browse all conditions

Mantle Cell Lymphoma trial results

Recruiting

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

NCT07225439

Conditions
B-cell Non Hodgkin Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +30 more
Locations
  • Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center Cleveland, Ohio, United States
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute Cleveland, Ohio, United States
View Trial Details
Recruiting

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT05976763

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
View all 238 locations
View Trial Details
Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Chao Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
View all 29 locations
View Trial Details
Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +37 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
View all 115 locations
View Trial Details
Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996

Conditions
B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • Ucsf Fresno Fresno, California, United States
  • Kaiser Permanente Southern California Irvine, California, United States
View all 155 locations
View Trial Details
Recruiting

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

NCT06697184

Conditions
CLL, Chronic Disease, Chronic Lymphocytic Leukemia, +22 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana, United States
  • The University of Kansas Cancer Center Westwood, Kansas, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 17 locations
View Trial Details

Related conditions